DCGI recommends Serum Institute’s qHPV vaccine against cervical cancer

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Medlarge Featured, Hospitals, Latest
Yashoda Super Specialty Kaushambi

The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.

“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.

The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).

The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.